News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim GmbH Release: Data Presented at EASD Support Safety Profile of Trajenta® (Linagliptin) In Broad Range of Adults With Type 2 Diabetes



9/24/2013 6:38:50 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented at the 49th European Association of Diabetes (EASD) Annual Meeting.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES